281 related articles for article (PubMed ID: 37775827)
1. A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer's disease patients from controls.
Pesämaa I; Müller SA; Robinson S; Darcher A; Paquet D; Zetterberg H; Lichtenthaler SF; Haass C
Mol Neurodegener; 2023 Sep; 18(1):70. PubMed ID: 37775827
[TBL] [Abstract][Full Text] [Related]
2. A MICROGLIAL ACTIVITY STATE BIOMARKER PANEL DIFFERENTIATES FTD-GRANULIN AND ALZHEIMER'S DISEASE PATIENTS FROM CONTROLS.
Pesämaa I; Müller SA; Robinson S; Darcher A; Paquet D; Zetterberg H; Lichtenthaler SF; Haass C
bioRxiv; 2023 Jun; ():. PubMed ID: 37398209
[TBL] [Abstract][Full Text] [Related]
3. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations.
Huang M; Modeste E; Dammer E; Merino P; Taylor G; Duong DM; Deng Q; Holler CJ; Gearing M; Dickson D; Seyfried NT; Kukar T
Acta Neuropathol Commun; 2020 Oct; 8(1):163. PubMed ID: 33028409
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
5. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
6. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A
J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275
[TBL] [Abstract][Full Text] [Related]
7. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.
Takahashi H; Klein ZA; Bhagat SM; Kaufman AC; Kostylev MA; Ikezu T; Strittmatter SM;
Acta Neuropathol; 2017 May; 133(5):785-807. PubMed ID: 28070672
[TBL] [Abstract][Full Text] [Related]
8. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
[TBL] [Abstract][Full Text] [Related]
9. Reduced TREM2 activation in microglia of patients with Alzheimer's disease.
Okuzono Y; Sakuma H; Miyakawa S; Ifuku M; Lee J; Das D; Banerjee A; Zhao Y; Yamamoto K; Ando T; Sato S
FEBS Open Bio; 2021 Nov; 11(11):3063-3080. PubMed ID: 34523252
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the Role of TREM2 in Alzheimer's Disease.
Ulrich JD; Ulland TK; Colonna M; Holtzman DM
Neuron; 2017 Apr; 94(2):237-248. PubMed ID: 28426958
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2).
Zhong L; Wang Z; Wang D; Wang Z; Martens YA; Wu L; Xu Y; Wang K; Li J; Huang R; Can D; Xu H; Bu G; Chen XF
Mol Neurodegener; 2018 Mar; 13(1):15. PubMed ID: 29587871
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease.
McQuade A; Kang YJ; Hasselmann J; Jairaman A; Sotelo A; Coburn M; Shabestari SK; Chadarevian JP; Fote G; Tu CH; Danhash E; Silva J; Martinez E; Cotman C; Prieto GA; Thompson LM; Steffan JS; Smith I; Davtyan H; Cahalan M; Cho H; Blurton-Jones M
Nat Commun; 2020 Oct; 11(1):5370. PubMed ID: 33097708
[TBL] [Abstract][Full Text] [Related]
13. Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model.
Meilandt WJ; Ngu H; Gogineni A; Lalehzadeh G; Lee SH; Srinivasan K; Imperio J; Wu T; Weber M; Kruse AJ; Stark KL; Chan P; Kwong M; Modrusan Z; Friedman BA; Elstrott J; Foreman O; Easton A; Sheng M; Hansen DV
J Neurosci; 2020 Feb; 40(9):1956-1974. PubMed ID: 31980586
[No Abstract] [Full Text] [Related]
14. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.
Reifschneider A; Robinson S; van Lengerich B; Gnörich J; Logan T; Heindl S; Vogt MA; Weidinger E; Riedl L; Wind K; Zatcepin A; Pesämaa I; Haberl S; Nuscher B; Kleinberger G; Klimmt J; Götzl JK; Liesz A; Bürger K; Brendel M; Levin J; Diehl-Schmid J; Suh J; Di Paolo G; Lewcock JW; Monroe KM; Paquet D; Capell A; Haass C
EMBO J; 2022 Feb; 41(4):e109108. PubMed ID: 35019161
[TBL] [Abstract][Full Text] [Related]
15. CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia.
Heywood WE; Hallqvist J; Heslegrave AJ; Zetterberg H; Fenoglio C; Scarpini E; Rohrer JD; Galimberti D; Mills K
Neurobiol Aging; 2018 Dec; 72():171-176. PubMed ID: 30292090
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia.
Hüttenrauch M; Ogorek I; Klafki H; Otto M; Stadelmann C; Weggen S; Wiltfang J; Wirths O
Acta Neuropathol Commun; 2018 Oct; 6(1):108. PubMed ID: 30340518
[TBL] [Abstract][Full Text] [Related]
18. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia.
van der Ende EL; Morenas-Rodriguez E; McMillan C; Grossman M; Irwin D; Sanchez-Valle R; Graff C; Vandenberghe R; Pijnenburg YAL; Laforce R; Ber IL; Lleo A; Haass C; Suarez-Calvet M; van Swieten JC; Seelaar H
Neurobiol Aging; 2021 Jul; 103():158.e1-158.e5. PubMed ID: 33896652
[TBL] [Abstract][Full Text] [Related]
19. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
20. Soluble TREM2: Innocent bystander or active player in neurological diseases?
Filipello F; Goldsbury C; You SF; Locca A; Karch CM; Piccio L
Neurobiol Dis; 2022 Apr; 165():105630. PubMed ID: 35041990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
